ERBB2 and breast carcinoma: Pathological biopsy remains the gold standard for determining HER2 status preoperatively; however, due to the heterogeneity of breast cancer and the sampling limitations of core needle biopsy, there is a need for methods that can comprehensively assess HER2 status before surgery [4, 5].